Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...
NEOK Bio, Inc., a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving ...
15don MSN
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve ...
Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...
NetTargets employs an AI system that combines multi-omics data with neural network modelling for drug discovery.
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to ...
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...
In patients with early-stage HER2-positive breast cancer in the DESTINY-Breast 05 and the DESTINY-Breast 11 trials, ...
Global Cancer Antibody Drug Conjugates Market Opportunity USD 70 Billion Opportunty By 2031 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback